Inceptionr LLC Sells 4,198 Shares of Biogen Inc. $BIIB

Inceptionr LLC cut its position in shares of Biogen Inc. (NASDAQ:BIIB) by 44.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,302 shares of the biotechnology company’s stock after selling 4,198 shares during the quarter. Inceptionr LLC’s holdings in Biogen were worth $743,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC bought a new stake in shares of Biogen during the 2nd quarter valued at $25,000. Accredited Wealth Management LLC grew its position in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the period. Rothschild Investment LLC increased its stake in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares in the last quarter. True Wealth Design LLC increased its stake in shares of Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares in the last quarter. Finally, WFA of San Diego LLC purchased a new position in Biogen during the 2nd quarter valued at about $32,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BIIB. Wolfe Research set a $231.00 price objective on shares of Biogen in a report on Monday, February 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Piper Sandler boosted their price target on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Morgan Stanley set a $190.00 price target on Biogen in a research note on Sunday, February 8th. Finally, Wells Fargo & Company raised their price objective on Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a research report on Sunday, February 8th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $205.04.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.18% of the company’s stock.

Biogen Stock Up 1.8%

NASDAQ:BIIB opened at $188.24 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The firm has a market cap of $27.63 billion, a P/E ratio of 21.37, a P/E/G ratio of 1.47 and a beta of 0.15. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The firm has a 50-day simple moving average of $183.31 and a two-hundred day simple moving average of $165.80.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm posted $3.44 earnings per share. The business’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.